Concepedia

Author

Suzanne Lentzsch

Columbia University Irving Medical CenterORCID

Also Known As

Jae Hoon Lee, Katja Weisel, S Lentzsch, S. Lentzsch, SUZANNE LENTZSCH, Suzanne Lentzsch, Voorhees, Peter M.

499

Publications

17.3K

Citations

58

H-Index

99

Concepts

All Affiliations

Columbia University Irving Medical CenterColumbia UniversityEmory UniversityCornell UniversityIcahn School of Medicine at Mount Sinai
SL

About

Suzanne Lentzsch is an author at Columbia University Irving Medical Center specializing in medicine, immunology, and immunotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

21

39

2.7K

2

Cell Biology

14

15

1.9K

3

Health Sciences

12

14

901

4

Public Health

1

1

17

5

Blood Transplantation

1

1

17

Suzanne Lentzsch

×

129

Publications

10.1K

Citations

50

H-Index

YearCitations

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Faith E. Davies, Noopur Raje, Teru Hideshima,

Blood

2001

901

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

D. Gupta, SP Treon, Yoshihito Shima,

Leukemia

2001

554

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

Richard LeBlanc, Laurence Catley, Teru Hideshima,

PubMed

2002

456

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Ajai Chari, Attaya Suvannasankha, Joseph W. Fay,

Blood

2017

438

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

Klaus Podar, Yu‐Tzu Tai, Faith E. Davies,

Blood

2001

417

Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

Meletios Α. Dimopoulos, Jens Hillengaß, Saad Z. Usmani,

Journal of Clinical Oncology

2015

387

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Paul G. Richardson, David S. Siegel, Ravi Vij,

Blood

2014

380

International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

Evangelos Terpos, Gareth J. Morgan, Meletios Α. Dimopoulos,

Journal of Clinical Oncology

2013

352

Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Andrew Spencer, Suzanne Lentzsch, Katja Weisel,

Haematologica

2018

254

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

Shaji Kumar, Sergio Giralt, Edward A. Stadtmauer,

Blood

2009

230

Page 1